Fate Therapeutics Inc (NASDAQ:FATE) Director Redmile Group, Llc acquired 3,703,704 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were bought at an average cost of $13.50 per share, with a total value of $50,000,004.00. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

NASDAQ:FATE traded up $0.34 during mid-day trading on Thursday, hitting $15.67. The company’s stock had a trading volume of 503,600 shares, compared to its average volume of 638,765. Fate Therapeutics Inc has a fifty-two week low of $3.50 and a fifty-two week high of $16.49. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $834.94 million, a PE ratio of -15.14 and a beta of 1.76.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. Fate Therapeutics had a negative return on equity of 95.07% and a negative net margin of 1,387.53%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. research analysts expect that Fate Therapeutics Inc will post -1.18 EPS for the current year.

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “hold” rating and issued a $12.00 price target on shares of Fate Therapeutics in a research report on Tuesday, August 7th. BidaskClub lowered shares of Fate Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 26th. Zacks Investment Research raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 6th. Citigroup assumed coverage on shares of Fate Therapeutics in a research report on Wednesday, August 1st. They issued a “buy” rating and a $20.00 price target for the company. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $25.00 price target on shares of Fate Therapeutics in a research report on Tuesday, September 18th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.29.

A number of institutional investors have recently modified their holdings of FATE. Quantbot Technologies LP bought a new stake in Fate Therapeutics during the first quarter worth about $107,000. Jane Street Group LLC bought a new stake in Fate Therapeutics during the second quarter worth about $116,000. PNC Financial Services Group Inc. bought a new stake in Fate Therapeutics during the second quarter worth about $120,000. Quantitative Systematic Strategies LLC bought a new stake in Fate Therapeutics during the second quarter worth about $129,000. Finally, First Mercantile Trust Co. grew its stake in Fate Therapeutics by 113.7% during the second quarter. First Mercantile Trust Co. now owns 12,899 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 6,863 shares during the last quarter. 80.61% of the stock is currently owned by hedge funds and other institutional investors.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Recommended Story: Diversification in Your Portfolio

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.